Cetuximab + Oxaliplatin + Capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colorectal Cancer
Conditions
Colorectal Cancer, Neoplasm Metastasis
Trial Timeline
Jun 1, 2004 → Jun 1, 2015
NCT ID
NCT00444678About Cetuximab + Oxaliplatin + Capecitabine
Cetuximab + Oxaliplatin + Capecitabine is a phase 2 stage product being developed by Eli Lilly for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00444678. Target conditions include Colorectal Cancer, Neoplasm Metastasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00444678 | Phase 2 | Completed |
Competing Products
20 competing products in Colorectal Cancer